Transcripta Bio, an AI-driven drug discovery startup, has raised $24 million to advance its neurological disease therapies. The funding will support clinical preparations for conditions like autism spectrum disorder and muscular dystrophy, leveraging AI models that analyze gene expression data to identify promising compounds. This approach could significantly improve the efficiency of drug development by reducing risks early in the process.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
Ali NematiWritten by Ali
